Entropy Technologies LP Has $606,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Entropy Technologies LP decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 33.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,400 shares of the medical equipment provider’s stock after selling 4,185 shares during the period. Entropy Technologies LP’s holdings in Hologic were worth $606,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the third quarter valued at about $25,000. General Partner Inc. bought a new position in Hologic in the fourth quarter worth approximately $26,000. First Horizon Advisors Inc. grew its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Cromwell Holdings LLC raised its position in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the period. Finally, Covestor Ltd raised its holdings in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 1.2 %

Shares of HOLX stock opened at $64.47 on Wednesday. Hologic, Inc. has a 12-month low of $63.62 and a 12-month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a 50 day moving average of $71.80 and a 200-day moving average of $77.57. The firm has a market cap of $14.55 billion, a P/E ratio of 20.34, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada reduced their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Evercore ISI decreased their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $80.00 to $75.00 in a report on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Stephens restated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.